CAPÍTULO 5: HIPERTENSIÓN ARTERIAL: IECA-ARA-FINERENONA, ¿OTROS FÁRMACOS ANTIHIPERTENSIVOS?
DOI:
https://doi.org/10.47196/diab.v58i2Sup.788Palabras clave:
presión arterial, diabetes mellitus, enfermedad renalResumen
La hipertensión arterial (HTA) juega un rol capital en la enfermedad renal (ER), por lo cual la evaluación en forma precisa es esencial. La HTA puede acelerar la progresión de la ER, su presencia, por otro lado, puede dificultar el control adecuado de la presión arterial (PA) y esta combinación aumenta significativamente el riesgo de eventos CV en la población con ERC. La PA de consultorio (PAC) es necesaria, pero no suficiente en pacientes con ERC, por lo tanto, es recomendable complementar la evaluación con automonitoreo de la PA (AMPA), monitoreo domiciliario de la PA (MDPA) y monitoreo ambulatorio de la PA (MAPA), según disponibilidad.
Un escenario particular es el paciente en tratamiento sustitutivo (hemodiálisis) donde la PA (pre, intra y pos) no es adecuada para indicar tratamiento y no se relaciona con resultados CV. El MAPA de 44 horas es la recomendación para tomar conductas terapéuticas que modifiquen el pronóstico CV en este contexto.
Citas
I. Hebert SA, Ibrahim HN. Hypertension management in patients with chronic kidney disease. Methodist DeBakey Cardiovasc J 2022;18(4):41-49.
II. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int 2021 Mar;99(3S):S1-S87.
III. Sarafidis PA, Persu A, Agarwal R, Burnier M, de Leeuw P, Ferro C, et al. Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH). J Hypertens 2017 Apr;35(4):657-676.
IV. The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103-16. doi: 10.1056/NEJMoa1511939.
V. Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018 Sep 1;39(33):3021-3104. doi: 10.1093/eurheartj/ehy339.
VI. de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, Rosas SE, Rossing P, Bakris G. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 2022 Dec 1;45(12):3075-3090. doi: 10.2337/dci22-0027.
VII. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison-Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018 Jun;71(6):e13-e115. doi: 10.1161/HYP.0000000000000065. Epub 2017 Nov 13. Erratum in: Hypertension 2018 Jun;71(6):e140-e144. PMID: 29133356.
VIII. Brenner MB, Cooper ME, de Zeeuw D, Keane WF, et al. RENAAL Study Investigators. N Engl J Med 2001; 345:861-869. doi: 10.1056/NEJMoa011161.
IX. Rodby RA, Rohde RD, Clarke WR, Hunsicker LG, Anzalone DA, Atkins RC, Ritz E, Lewis EJ. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group. Nephrol Dial Transplant 2000 Apr;15(4):487-97. doi: 10.1093/ndt/15.4.487.
X. Sica DA. The African American Study of Kidney Disease and Hypertension (AASK) trial: what more have we learned? J Clin Hypertens (Greenwich) 2003 Mar-Apr;5(2):159-67. doi: 10.1111/j.1524-6175.2003.01924.x.
XI. Damianaki A, Polychronopoulou E, Wuerzner G, et al. New aspects in the management of hypertension in patients with chronic kidney disease not on renal replacement therapy. High Blood Press Cardiovasc Prev 2022;29:125-135. Doi: 10.1007/s40292-021-00495-1.
XII. Agarwal R, Sinha AD, Cramer AE, Balmes-Fenwick M, Dickinson JH, Ouyang F, Tu W. Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med 2021 Dec 30;385(27):2507-2519.
XIII. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015;386(10008):2059-2068. doi: 10.1016/S0140-6736(15)00257-3.
XIV. Bhandari S, Ives N, Brettell EA, Valente M, Cockwell P, Topham PS, et al. Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial. Nephrol Dial Transplant 2016 Feb;31(2):255-61. doi: 10.1093/ndt/gfv346.
XV. Remuzzi G, Macia M, Ruggenenti P. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. J Am Soc Nephrol 2006 Apr;17(4 Suppl 2):S90-7.
XVI. González-Juanatey JR, Górriz JL, Ortiz A, Valle A, Soler MJ, Facila L. Cardiorenal benefits of finerenone: protecting kidney and heart. Ann Med 2023 Dec;55(1):502-513. doi: 10.1080/07853890.2023.2171110.
XVII. Ruilope LM, Agarwal R, Anker SD, Filippatos G, Pitt B, Rossing P, et al. Blood pressure and cardiorenal outcomes with finerenone in chronic kidney disease in type 2 diabetes. Hypertension 2022 Dec;79(12):2685-95.
XVIII. Strippoli GFM, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 2006 Oct 18;2006(4):CD006257.
XIX. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000 Jan 22;355(9200):253-9.
XX. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021 Mar;99(3S):S1-87.
XXI. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. Summary of revisions: Standards of Care in Diabetes 2023. Diabetes Care 2023 Jan 1;46(Suppl 1):S5-9.
XXII. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004 Nov 4;351(19):1952-61.
XXIII. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, et al. Renoprotectiva efect of the angiotensin-receptor antagonist irbersartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001 sept 20;345(12):851-860.
XXIV. Wu HY, Peng CL, Chen PC, Chiang CK, Chang CJ, Huang JW, et al. Comparative effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers for major renal outcomes in patients with diabetes: a 15-year cohort study. PLoS One 2017 May 15;12(5):e0177654.
XXV. Wang K, Hu J, Luo T, Wang Y, Yang S, Qing H, Cheng Q, Li Q. Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality and renal outcomes in patients with diabetes and albuminuria: a systematic review and meta-analysis. Kidney Blood Press Res 2018;43(3):768-779.
XXVI. Gorriz JL, Gonzales-Juanetey JR, Facila L, Soler MJ, Valle A, Ortiz A. Finerenona: completando el abordaje del paciente con enfermedad renal y diabetes. Rev Nefrol 2023;43(4):386-398.
XXVII. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al.; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845.
XXVIII. Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA 2015 Sep 1;314(9):884-94.
XXIX. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020 Dec 3;383(23):2219-29.
XXX. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 2021 Dec 9;385(24):2252-63.
XXXI. Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 2022 Feb 10;43(6):474-84.
XXXII. ClinicalTrials.gov. Disponible en: https://clinicaltrials.gov/study/NCT05047263.
XXXIII. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al, on behalf of the American Diabetes Association. Introduction and methodology: Standards of Care in Diabetes 2023. Diabetes Care 2023 Jan 1;46(Suppl 1):S1-S4. doi: 10.2337/dc23-Sint.
XXXIV. Blonde L, Umpierrez GE, Reddy SS, McGill JB, Berga SL, Bush M, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: developing a diabetes mellitus comprehensive care plan-2022 Update. Endocr Pract 2022 Oct;28(10):923-1049.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2024 a nombre de los autores. Derechos de reproducción: Sociedad Argentina de Diabetes
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
